Matica Biotechnology Inc., a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing, has entered a strategic development partnership with CytoImmune, a biotechnology company based in Puerto Rico that focuses on innovative cell therapies for cancer treatment using proprietary technology.
 
Under this partnership, Matica Bio will produce viral vectors at its purpose-built GMP facility, while CytoImmune will manufacture its cell therapy at its Puerto Rico facility for IND submission.
 
“The combined effort to advance a clinical cell therapy program is an exciting opportunity for both organizations,” said Matica Bio CEO Paul Kim. “We believe this collaboration is essential for mutual growth and will help deliver a product manufactured by experts in viral vector and cell therapy. CytoImmune’s expertise in research, development, and manufacturing of cell therapies complements Matica Bio’s capabilities in viral vector process development, GMP production, product release, and stability assessment. Together, we will ensure continued success and foster future innovations in the advanced therapies space.”
 
Dr. Jose Vidal, CytoImmune CEO said, “We are focused on innovating and delivering therapies that revolutionize medicine and better lives. Working with Matica Bio, we know we will not only be able to invent better processes for solving for cures but also processes for accelerating medicines through approvals.”
 
In addition to its strategic partnership with CytoImmune, Matica Bio is collaborating with other industry leaders, including Sartorius Stedim Biotech to develop and optimize advanced viral vector manufacturing technologies for large-scale production.